Rallybio CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

16 Mar 2026

RLYB

10-K: Rallybio Pivots with Candid Merger, Focuses on CVRs

Rallybio Corporation announces a definitive merger agreement with Candid Therapeutics, shifting its strategic focus to T-cell engager therapeutics and monetizing legacy assets through Contingent Value Rights.

NASDAQ

13 Mar 2025

RLYB

Rallybio CORP

10-K: Rallybio Reports Full Year 2024 Results, Provides Clinical Pipeline Update

Rallybio's 10-K filing summarizes the company's financial performance for 2024 and provides updates on its clinical development programs, including RLYB212 and RLYB116.

NASDAQ

12 Mar 2024

RLYB

Rallybio CORP

10-K: Rallybio Corporation 2023 Annual Report: Focus on Clinical Programs and Strategic Growth

Rallybio's 2023 annual report highlights the company's progress in clinical development, particularly for RLYB212 and RLYB116, while also outlining strategic shifts and financial results.